Exact Mass: 528.0904

Exact Mass Matches: 528.0904

Found 22 metabolites which its exact mass value is equals to given mass value 528.0904, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Lactose citrate

1,8,9,10-tetrahydroxy-5-(hydroxymethyl)-7-{[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}-4,6,11,15-tetraoxatricyclo[7.3.3.0^{5,10}]pentadecane-3,12,14-trione

C18H24O18 (528.0963)


   

CHLOROCYCLINONE C

CHLOROCYCLINONE C

C26H21ClO10 (528.0823)


   

O-(4-deoxy-alpha-L-erythro-hex-4-enopyranosyluronic acid)-(1<*>4)-O-(beta-D-mannopyranuronic acid)-(1<*>4)-O-D-mannopyranuronic acid

O-(4-deoxy-alpha-L-erythro-hex-4-enopyranosyluronic acid)-(1<*>4)-O-(beta-D-mannopyranuronic acid)-(1<*>4)-O-D-mannopyranuronic acid

C18H24O18 (528.0963)


   

4,5-di-O-caffeoyldaucic acid

4,5-di-O-caffeoyldaucic acid

C25H20O13 (528.0904)


   

Griseorhodin C

Griseorhodin C

C25H20O13 (528.0904)


   

(2S,3R,4R)-3,4-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-3,4-dihydro-2H-pyran-2,6-dicarboxylic acid

NCGC00385232-01!(2S,3R,4R)-3,4-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-3,4-dihydro-2H-pyran-2,6-dicarboxylic acid

C25H20O13 (528.0904)


   

(2S,3R,4R)-3,4-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-3,4-dihydro-2H-pyran-2,6-dicarboxylic acid [IIN-based: Match]

NCGC00385232-01!(2S,3R,4R)-3,4-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-3,4-dihydro-2H-pyran-2,6-dicarboxylic acid [IIN-based: Match]

C25H20O13 (528.0904)


   

(2S,3R,4S)-2-[(2S,3R,4R,5R,6S)-2-carboxy-6-[(2S,3R,4R,5R)-2-carboxy-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid

(2S,3R,4S)-2-[(2S,3R,4R,5R,6S)-2-carboxy-6-[(2S,3R,4R,5R)-2-carboxy-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid

C18H24O18 (528.0963)


   

4-O-[4-O-(4-Deoxy-beta-L-threo-hexa-4-enopyranuronosyl)-alpha-D-galactopyranuronosyl]-alpha-D-galactopyranuronic acid

4-O-[4-O-(4-Deoxy-beta-L-threo-hexa-4-enopyranuronosyl)-alpha-D-galactopyranuronosyl]-alpha-D-galactopyranuronic acid

C18H24O18 (528.0963)


   

1,8,9,10-Tetrahydroxy-5-(hydroxymethyl)-7-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,6,11,15-tetraoxatricyclo[7.3.3.05,10]pentadecane-3,12,14-trione

1,8,9,10-Tetrahydroxy-5-(hydroxymethyl)-7-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,6,11,15-tetraoxatricyclo[7.3.3.05,10]pentadecane-3,12,14-trione

C18H24O18 (528.0963)


   

3-[[2-(4-Bromophenyl)-1-oxoethyl]amino]-3-[4-[(4-fluorophenyl)methylamino]-3-nitrophenyl]propanamide

3-[[2-(4-Bromophenyl)-1-oxoethyl]amino]-3-[4-[(4-fluorophenyl)methylamino]-3-nitrophenyl]propanamide

C24H22BrFN4O4 (528.0808)


   

3,4,5-trihydroxy-6-[[3-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-5-sulino-3,4-dihydro-2H-chromen-7-yl]oxy]oxane-2-carboxylic acid

3,4,5-trihydroxy-6-[[3-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-5-sulino-3,4-dihydro-2H-chromen-7-yl]oxy]oxane-2-carboxylic acid

C22H24O13S (528.0938)


   

(3R,4S)-2-[(2S,3R,4R,5R)-2-carboxy-6-[(2S,4R,5R)-2-carboxy-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid

(3R,4S)-2-[(2S,3R,4R,5R)-2-carboxy-6-[(2S,4R,5R)-2-carboxy-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid

C18H24O18 (528.0963)


   

(2S,3R,4R)-3,4-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-3,4-dihydro-2H-pyran-2,6-dicarboxylic acid

(2S,3R,4R)-3,4-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-3,4-dihydro-2H-pyran-2,6-dicarboxylic acid

C25H20O13 (528.0904)


   

3-Carboxy-1-hydroxypropylthiamine diphosphate

3-Carboxy-1-hydroxypropylthiamine diphosphate

C16H26N4O10P2S (528.0845)


A 1,3-thiazolium cation that is 1,3-thiazol-3-ium substituted by a methyl group at position 4, a (4-amino-2-methylpyrimidin-5-yl)methyl group at position 3, a 3-carboxy-1-hydroxypropyl at position 2 and a 2-{[hydroxy(phosphonooxy)phosphoryl]oxy}ethyl group at position 5.

   

KRAS G12C inhibitor 19

KRAS G12C inhibitor 19

C25H19ClF2N4O3S (528.0834)


KRAS G12C inhibitor 19 is a potent inhibitor of KRAS G12C. KRAS G12C inhibitor 19 significantly inhibits tumor growth (extracted from patent WO2021118877A1)[1].

   

3,4-bis({[3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy})-3,4-dihydro-2h-pyran-2,6-dicarboxylic acid

3,4-bis({[3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy})-3,4-dihydro-2h-pyran-2,6-dicarboxylic acid

C25H20O13 (528.0904)


   

(2s,3r,4s)-3,4-bis({[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy})-3,4-dihydro-2h-pyran-2,6-dicarboxylic acid

(2s,3r,4s)-3,4-bis({[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy})-3,4-dihydro-2h-pyran-2,6-dicarboxylic acid

C25H20O13 (528.0904)


   

(2r,3r,3'r,4's,9r,9as)-3,3',4,4',9,10'-hexahydroxy-7-methoxy-7'-methyl-3',4',9,9a-tetrahydro-3h-spiro[naphtho[2,3-b]furan-2,2'-pyrano[3,2-g]isochromene]-5,8,9'-trione

(2r,3r,3'r,4's,9r,9as)-3,3',4,4',9,10'-hexahydroxy-7-methoxy-7'-methyl-3',4',9,9a-tetrahydro-3h-spiro[naphtho[2,3-b]furan-2,2'-pyrano[3,2-g]isochromene]-5,8,9'-trione

C25H20O13 (528.0904)


   

methyl 2-chloro-6,8-dihydroxy-9-[(1s)-1-[(2-hydroxyacetyl)oxy]ethyl]-1-methoxy-3-methyl-7,12-dioxotetraphene-10-carboxylate

methyl 2-chloro-6,8-dihydroxy-9-[(1s)-1-[(2-hydroxyacetyl)oxy]ethyl]-1-methoxy-3-methyl-7,12-dioxotetraphene-10-carboxylate

C26H21ClO10 (528.0823)


   

methyl 2-chloro-6,8-dihydroxy-9-{1-[(2-hydroxyacetyl)oxy]ethyl}-1-methoxy-3-methyl-7,12-dioxotetraphene-10-carboxylate

methyl 2-chloro-6,8-dihydroxy-9-{1-[(2-hydroxyacetyl)oxy]ethyl}-1-methoxy-3-methyl-7,12-dioxotetraphene-10-carboxylate

C26H21ClO10 (528.0823)


   

3,3',4,4',9,10'-hexahydroxy-7-methoxy-7'-methyl-3',4',9,9a-tetrahydro-3h-spiro[naphtho[2,3-b]furan-2,2'-pyrano[3,2-g]isochromene]-5,8,9'-trione

3,3',4,4',9,10'-hexahydroxy-7-methoxy-7'-methyl-3',4',9,9a-tetrahydro-3h-spiro[naphtho[2,3-b]furan-2,2'-pyrano[3,2-g]isochromene]-5,8,9'-trione

C25H20O13 (528.0904)